PMC:7600245 / 21790-22263 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T97","span":{"begin":436,"end":439},"obj":"Body_part"}],"attributes":[{"id":"A97","pred":"fma_id","subj":"T97","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":" SARS-CoV-2 infection is being evaluated in a large randomized, double-blind, controlled with placebo clinical trial for health care providers exposed to COVID-19 patients (NCT04405271; n = 1378).\n\n2.6. Favipiravir (Avigan, T-705)\nFavipiravir was originally developed by Fujifilm group, Japan. It is a pyrazine-carboxamide derivative (Figure 4) with a broad-spectrum antiviral activity. It selectively and potently inhibits the RdRp of RNA viruses [69]. Favipiravir is a pr"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T78","span":{"begin":1,"end":9},"obj":"Disease"},{"id":"T79","span":{"begin":12,"end":21},"obj":"Disease"},{"id":"T80","span":{"begin":154,"end":162},"obj":"Disease"}],"attributes":[{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A79","pred":"mondo_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A80","pred":"mondo_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":" SARS-CoV-2 infection is being evaluated in a large randomized, double-blind, controlled with placebo clinical trial for health care providers exposed to COVID-19 patients (NCT04405271; n = 1378).\n\n2.6. Favipiravir (Avigan, T-705)\nFavipiravir was originally developed by Fujifilm group, Japan. It is a pyrazine-carboxamide derivative (Figure 4) with a broad-spectrum antiviral activity. It selectively and potently inhibits the RdRp of RNA viruses [69]. Favipiravir is a pr"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T201","span":{"begin":44,"end":45},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T202","span":{"begin":300,"end":301},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T203","span":{"begin":350,"end":351},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T204","span":{"begin":377,"end":385},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T205","span":{"begin":440,"end":447},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T206","span":{"begin":469,"end":470},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":" SARS-CoV-2 infection is being evaluated in a large randomized, double-blind, controlled with placebo clinical trial for health care providers exposed to COVID-19 patients (NCT04405271; n = 1378).\n\n2.6. Favipiravir (Avigan, T-705)\nFavipiravir was originally developed by Fujifilm group, Japan. It is a pyrazine-carboxamide derivative (Figure 4) with a broad-spectrum antiviral activity. It selectively and potently inhibits the RdRp of RNA viruses [69]. Favipiravir is a pr"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T296","span":{"begin":224,"end":229},"obj":"Chemical"},{"id":"T297","span":{"begin":280,"end":285},"obj":"Chemical"},{"id":"T298","span":{"begin":302,"end":310},"obj":"Chemical"},{"id":"T299","span":{"begin":311,"end":322},"obj":"Chemical"},{"id":"T301","span":{"begin":367,"end":376},"obj":"Chemical"}],"attributes":[{"id":"A296","pred":"chebi_id","subj":"T296","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A297","pred":"chebi_id","subj":"T297","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A298","pred":"chebi_id","subj":"T298","obj":"http://purl.obolibrary.org/obo/CHEBI_30953"},{"id":"A299","pred":"chebi_id","subj":"T299","obj":"http://purl.obolibrary.org/obo/CHEBI_23004"},{"id":"A300","pred":"chebi_id","subj":"T299","obj":"http://purl.obolibrary.org/obo/CHEBI_37622"},{"id":"A301","pred":"chebi_id","subj":"T301","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":" SARS-CoV-2 infection is being evaluated in a large randomized, double-blind, controlled with placebo clinical trial for health care providers exposed to COVID-19 patients (NCT04405271; n = 1378).\n\n2.6. Favipiravir (Avigan, T-705)\nFavipiravir was originally developed by Fujifilm group, Japan. It is a pyrazine-carboxamide derivative (Figure 4) with a broad-spectrum antiviral activity. It selectively and potently inhibits the RdRp of RNA viruses [69]. Favipiravir is a pr"}

{"project":"LitCovid-sentences","denotations":[{"id":"T160","span":{"begin":198,"end":202},"obj":"Sentence"},{"id":"T161","span":{"begin":203,"end":230},"obj":"Sentence"},{"id":"T162","span":{"begin":231,"end":293},"obj":"Sentence"},{"id":"T163","span":{"begin":294,"end":386},"obj":"Sentence"},{"id":"T164","span":{"begin":387,"end":453},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" SARS-CoV-2 infection is being evaluated in a large randomized, double-blind, controlled with placebo clinical trial for health care providers exposed to COVID-19 patients (NCT04405271; n = 1378).\n\n2.6. Favipiravir (Avigan, T-705)\nFavipiravir was originally developed by Fujifilm group, Japan. It is a pyrazine-carboxamide derivative (Figure 4) with a broad-spectrum antiviral activity. It selectively and potently inhibits the RdRp of RNA viruses [69]. Favipiravir is a pr"}

{"project":"LitCovid-PubTator","denotations":[{"id":"564","span":{"begin":163,"end":171},"obj":"Species"},{"id":"584","span":{"begin":1,"end":21},"obj":"Disease"},{"id":"585","span":{"begin":154,"end":162},"obj":"Disease"},{"id":"597","span":{"begin":428,"end":432},"obj":"Gene"},{"id":"599","span":{"begin":231,"end":242},"obj":"Chemical"},{"id":"600","span":{"begin":302,"end":322},"obj":"Chemical"},{"id":"601","span":{"begin":454,"end":465},"obj":"Chemical"}],"attributes":[{"id":"A564","pred":"tao:has_database_id","subj":"564","obj":"Tax:9606"},{"id":"A584","pred":"tao:has_database_id","subj":"584","obj":"MESH:C000657245"},{"id":"A585","pred":"tao:has_database_id","subj":"585","obj":"MESH:C000657245"},{"id":"A597","pred":"tao:has_database_id","subj":"597","obj":"Gene:43740578"},{"id":"A599","pred":"tao:has_database_id","subj":"599","obj":"MESH:C462182"},{"id":"A600","pred":"tao:has_database_id","subj":"600","obj":"MESH:D011718"},{"id":"A601","pred":"tao:has_database_id","subj":"601","obj":"MESH:C462182"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" SARS-CoV-2 infection is being evaluated in a large randomized, double-blind, controlled with placebo clinical trial for health care providers exposed to COVID-19 patients (NCT04405271; n = 1378).\n\n2.6. Favipiravir (Avigan, T-705)\nFavipiravir was originally developed by Fujifilm group, Japan. It is a pyrazine-carboxamide derivative (Figure 4) with a broad-spectrum antiviral activity. It selectively and potently inhibits the RdRp of RNA viruses [69]. Favipiravir is a pr"}